NextCell Pharma Secures Crucial Funding for Diabetes Cell Therapy
January 25, 2026, 3:32 pm
NextCell Pharma proposed a SEK 15 million directed share issue. This pivotal financing fuels ProTrans, their advanced cell therapy for type 1 diabetes. New strategic investors, specifically focused on diabetes and disease-modifying therapies, have significantly subscribed, alongside existing major shareholders. This infusion strengthens NextCell's capital position. Proceeds will directly advance ProTrans's critical clinical development and reinforce overall working capital. An Extraordinary General Meeting is scheduled for February 10, 2026, to formally approve this resolution. The strategic move targets crucial value-driving milestones efficiently. It diversifies the shareholder base and prudently limits existing shareholder dilution. This financing positions NextCell as a leader in regenerative medicine.
NextCell Pharma is advancing its groundbreaking cell therapy. The company proposes a SEK 15 million directed share issue. This move secures vital financing. It targets continued development of ProTrans. ProTrans is a leading drug candidate for type 1 diabetes.
The Board of Directors made this decision. They will present the proposal to an Extraordinary General Meeting. The meeting is set for February 10, 2026. This share issue involves 15,000,000 shares. Each share is priced at SEK 1.00. Gross proceeds will reach SEK 15 million. Transaction costs remain low. The company conducted the issue without a financial advisor.
New strategic investors are participating. They bring a clear commitment to type 1 diabetes research. A European specialist fund, focused on type 1 diabetes, joined. Rustan Panday, a prominent entrepreneur, is involved. Anders Eriksson and Mats Gustafsson, co-founders of the Foundation for Type 1 Diabetes Research, also invested. Michaëla Berglund and India von Platen, known for diabetes advocacy, contributed. An additional institutional investor is also part of this strategic group.
New investors subscribed for SEK 10 million. Existing major shareholders subscribed for the remaining SEK 5 million. Market interest exceeded the SEK 15 million target. The Board maintained the initial issue size. This balance attracts new long-term shareholders. It also keeps dilution for current shareholders at a responsible level.
The subscription price reflects market value. It was determined through arm's length negotiations. The price considers the volume-weighted average price (VWAP). This calculation spanned 10-20 trading days on Nasdaq First North Growth Market.
The decision to deviate from shareholders' preferential rights was deliberate. The company weighed all options. A preferential issue would take longer. It carries a higher risk of negative share price impact. A directed issue offers speed and cost-effectiveness. It is less complex. It specifically targets strategic, long-term investors. This approach diversifies the shareholder base. It strengthens NextCell Pharma's financial footing.
This financing is crucial. It supports NextCell in reaching key value-creating milestones. These milestones include ProTrans's clinical advancement. Funds will also bolster the company's working capital.
ProTrans represents a significant medical innovation. It is a patent-protected cell therapy platform. It uses allogeneic mesenchymal stromal cells (MSCs). These cells come from umbilical cord tissue. A proprietary algorithm optimizes cell selection. This ensures tailored treatment for specific indications.
In type 1 diabetes, ProTrans has shown remarkable results. A single infusion can preserve insulin production. It can delay disease progression for at least five years. This offers hope for millions. A Phase III trial is planned. It awaits a commercial partner. ProTrans is also being explored for other autoimmune conditions. It also targets various inflammatory diseases.
The proposed share issue will increase NextCell's capital. Share capital will rise by SEK 3,075,000. The total number of shares will increase by 15,000,000. This results in approximately 11.87% dilution.
The Extraordinary General Meeting requires shareholder approval. Major shareholders already signal strong support. Approximately 40 percent of the shares and votes are committed. They intend to vote in favor of the directed share issue. This widespread backing indicates confidence. It underscores the strategic importance of the funding.
NextCell Pharma operates beyond ProTrans development. Its subsidiaries contribute to the broader cell therapy ecosystem. Cellaviva is Scandinavia’s largest private stem cell bank. QVance provides quality services. It supports advanced therapy developers in the Nordic region. These entities reinforce NextCell's position. They highlight its comprehensive approach to regenerative medicine.
This financing strengthens NextCell's market presence. It reinforces its commitment to medical breakthroughs. The company continues to pioneer cell-based therapies. It focuses on critical unmet medical needs. This capital injection accelerates that mission. It brings a promising treatment closer to patients. It solidifies NextCell Pharma's role in the global biotech landscape. The Nasdaq First North Growth Market listing reflects its growth trajectory. Investors see long-term value in this clinical-stage company. The directed share issue is a strategic pivot. It empowers NextCell Pharma to lead in innovative diabetes care. It advances cell therapy solutions.
NextCell Pharma is advancing its groundbreaking cell therapy. The company proposes a SEK 15 million directed share issue. This move secures vital financing. It targets continued development of ProTrans. ProTrans is a leading drug candidate for type 1 diabetes.
The Board of Directors made this decision. They will present the proposal to an Extraordinary General Meeting. The meeting is set for February 10, 2026. This share issue involves 15,000,000 shares. Each share is priced at SEK 1.00. Gross proceeds will reach SEK 15 million. Transaction costs remain low. The company conducted the issue without a financial advisor.
New strategic investors are participating. They bring a clear commitment to type 1 diabetes research. A European specialist fund, focused on type 1 diabetes, joined. Rustan Panday, a prominent entrepreneur, is involved. Anders Eriksson and Mats Gustafsson, co-founders of the Foundation for Type 1 Diabetes Research, also invested. Michaëla Berglund and India von Platen, known for diabetes advocacy, contributed. An additional institutional investor is also part of this strategic group.
New investors subscribed for SEK 10 million. Existing major shareholders subscribed for the remaining SEK 5 million. Market interest exceeded the SEK 15 million target. The Board maintained the initial issue size. This balance attracts new long-term shareholders. It also keeps dilution for current shareholders at a responsible level.
The subscription price reflects market value. It was determined through arm's length negotiations. The price considers the volume-weighted average price (VWAP). This calculation spanned 10-20 trading days on Nasdaq First North Growth Market.
The decision to deviate from shareholders' preferential rights was deliberate. The company weighed all options. A preferential issue would take longer. It carries a higher risk of negative share price impact. A directed issue offers speed and cost-effectiveness. It is less complex. It specifically targets strategic, long-term investors. This approach diversifies the shareholder base. It strengthens NextCell Pharma's financial footing.
This financing is crucial. It supports NextCell in reaching key value-creating milestones. These milestones include ProTrans's clinical advancement. Funds will also bolster the company's working capital.
ProTrans represents a significant medical innovation. It is a patent-protected cell therapy platform. It uses allogeneic mesenchymal stromal cells (MSCs). These cells come from umbilical cord tissue. A proprietary algorithm optimizes cell selection. This ensures tailored treatment for specific indications.
In type 1 diabetes, ProTrans has shown remarkable results. A single infusion can preserve insulin production. It can delay disease progression for at least five years. This offers hope for millions. A Phase III trial is planned. It awaits a commercial partner. ProTrans is also being explored for other autoimmune conditions. It also targets various inflammatory diseases.
The proposed share issue will increase NextCell's capital. Share capital will rise by SEK 3,075,000. The total number of shares will increase by 15,000,000. This results in approximately 11.87% dilution.
The Extraordinary General Meeting requires shareholder approval. Major shareholders already signal strong support. Approximately 40 percent of the shares and votes are committed. They intend to vote in favor of the directed share issue. This widespread backing indicates confidence. It underscores the strategic importance of the funding.
NextCell Pharma operates beyond ProTrans development. Its subsidiaries contribute to the broader cell therapy ecosystem. Cellaviva is Scandinavia’s largest private stem cell bank. QVance provides quality services. It supports advanced therapy developers in the Nordic region. These entities reinforce NextCell's position. They highlight its comprehensive approach to regenerative medicine.
This financing strengthens NextCell's market presence. It reinforces its commitment to medical breakthroughs. The company continues to pioneer cell-based therapies. It focuses on critical unmet medical needs. This capital injection accelerates that mission. It brings a promising treatment closer to patients. It solidifies NextCell Pharma's role in the global biotech landscape. The Nasdaq First North Growth Market listing reflects its growth trajectory. Investors see long-term value in this clinical-stage company. The directed share issue is a strategic pivot. It empowers NextCell Pharma to lead in innovative diabetes care. It advances cell therapy solutions.